Janet Gersten, MD
Gynecology · Miami, FLNPI 1174506323
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.0% of the total across 26 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by AbbVie at 37.3% of the total. Reporting peaked in 2019 at $221 and has fallen 73.3% since, to $59 in 2023. That places this record below the midpoint for gynecology clinicians in FL, where the typical reported total is $857.
Across 26 payments — averaging $18.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$183
- Mylan Pharmaceuticals Inc.$54
- Therapeuticsmd, Inc.$54
- Astellas Pharma US Inc$38
- Coopersurgical, Inc.$32
- Myovant Sciences Inc.$29
- plus $101 from 5 others
Across 697 payments — averaging $9054.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Exeltis, USA Inc.$2.7M
- Eli Lilly$1.4M
- Mylan Inc.$913K
- Organon$468K
- Mylan Technologies Inc.$459K
- Merck$254K
- plus $128K from 4 others
What the payments were for
- Food & beverage$46695%
- Education$255%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 10 | $183 |
| Mylan Pharmaceuticals Inc. | 3 | $54 |
| Therapeuticsmd, Inc. | 3 | $54 |
| Astellas Pharma US Inc | 2 | $38 |
| Coopersurgical, Inc. | 2 | $32 |
| Myovant Sciences Inc. | 1 | $29 |
| AMAG Pharmaceuticals, Inc. | 1 | $25 |
| Bayer | 1 | $24 |
| Exeltis, USA Inc. | 1 | $21 |
| Sage Therapeutics, LLC | 1 | $17 |
| Lupin Inc. | 1 | $15 |
How this compares
$491 in reported general payments places this provider in the 35th percentile of 290 gynecology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PremproEstrogen,con/M-Progest Acet | 15 | $4,532 |
| Estradiol | 20 | $828 |
Paid to pharmacies, not to this prescriber.
Other gynecology in Miami
- Steven ChavoustieMiami$113K
- Tarek BardawilMiami$15K
- Jorge GarciaMiami$10K
- George AttiaMiami$8K
- Aileen CaceresKissimmee$406K
- Parveen VahoraNew Port Richey$327K
- James KondrupVenice$310K
- Andrea GallowayThe Villages$252K
- Jessica VaughtOrlando$129K
- Marshall BovelskyMelbourne$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.